title: Contraction of occult choroidal neovascular membrane and rupture of the retinal pigment following verteporfin and bevacizumab treatment.
authors.forename: Sara Brandi
authors.initials: SB
authors.lastname: Bloch
authors.forename: Ahmed
authors.initials: A
authors.lastname: Bedda
authors.forename: Ahmed M
authors.initials: AM
authors.lastname: Abdel Hadi
authors.forename: Michael
authors.initials: M
authors.lastname: Larsen
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000627:therapeutic use; D001485:Basement Membrane / Q000473:pathology; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000209:etiology*; D003286:Contracture / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy; D008297:Male; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use; D011166:Porphyrins / Q000008:administration & dosage* / Q000627:therapeutic use; D011183:Postoperative Complications; D012164:Retinal Diseases / Q000175:diagnosis / Q000209:etiology*; D055213:Retinal Pigment Epithelium / Q000473:pathology*; D012422:Rupture, Spontaneous; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D000077362:Verteporfin
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D017319:Photosensitizing Agents; D011166:Porphyrins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000077362:Verteporfin; D000068258:Bevacizumab